Chronic Myeloid Leukemia, BCR-ABL1+
About
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.Type | Biomarker(s) | Cancer type | Therapy(ies) | |
---|---|---|---|---|
Sensitivity (+) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Dasatinib | |
Sensitivity (+) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Dasatinib | |
Sensitivity (+) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Dasatinib | |
Sensitivity (+) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Imatinib | |
Sensitivity (+) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Imatinib | |
Sensitivity (+) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Nilotinib | |
Sensitivity (+) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Nilotinib | |
Sensitivity (+) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Asciminib |